Tumoral ANXA1 Is a Predictive Marker for Sunitinib Treatment of Renal Cancer Patients

Background and aims: There is no established predictive marker for the treatment of renal cancer. Metastatic renal cell carcinoma (mRCC) patients are often treated with sunitinib, a tyrosine kinase inhibitor. Sunitinibs anti-cancer effect is at least partly mediated through interfering with angiogen...

Descripción completa

Detalles Bibliográficos
Autores principales: Niinivirta, Marjut, Enblad, Gunilla, Edqvist, Per-Henrik, Pontén, Fredrik, Dragomir, Anca, Ullenhag, Gustav J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705999/
https://www.ncbi.nlm.nih.gov/pubmed/29187872
http://dx.doi.org/10.7150/jca.20889

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705999/
https://www.ncbi.nlm.nih.gov/pubmed/29187872
http://dx.doi.org/10.7150/jca.20889

Ejemplares similares